Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by Johns Hopkins University
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Martin G. Pomper, MD, PhD, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT01894646
First received: June 27, 2013
Last updated: March 30, 2015
Last verified: March 2015
  Purpose

Currently, only three radiotracers, (2-[18F]FA, 6-[18F]FA and [18F]AZAN), are available for studying α4β2-nicotinic acetylcholine receptors (α4β2-nAChR) in human brain using PET imaging. A crucial problem for 2-[18F] FA, 6-[18F] FA and ([18F] AZAN is low binding potential (BP) in extrathalamic (ET) regions, including hippocampus, cortex and caudate which have lower receptor densities than the thalamus. The importance of imaging ET-α4β2-nAChRs (ET-nAChR) has emerged from the post-mortem demonstration of altered densities of ET-nAChRs (but not thalamic nAChR) in neurodegenerative diseases and schizophrenia. PET imaging of ET-nAChR may prove to be useful in both detecting early changes and following functional deterioration in neurodegenerative diseases such as Alzheimers disease. Furthermore, PET imaging of ET-nAChR may allow investigation and development of new therapies acting on the acetylcholine system.

The imaging drawbacks of the presently available nAChR radioligands have initiated the development of radioligands with greater binding potential by several research groups. The available pre-clinical data on our new radioligand [18F](-)-JHU86428 ([18F]XTRA) suggest that this radioligand is superior to 2-[18F]FA for quantitative PET imaging of α4β2-nAChR (Gao, J. Med. Chem, 2008). In baboon PET studies [18F]XTRA exhibits 200% greater brain uptake, 300% higher BPs and reaches steady-state in approximately 1.5 h in cortical regions post-bolus administration versus 6-8 h for 2-[18F]FA. In vitro binding assays shows greater binding affinity of XTRA and similar nAChR-subtype selectivity in comparison with 2-FA. Both ligands bind selectively with the β2-subtypes that are predominant nAChR subtypes in the mammal brain and display little binding affinity at ganglionic α3β4-nAChR.

The current planned human protocol will be conducted to (1) determine brain distribution (brain uptake) and test the reproducibility (in test-retest design) of [18F]XTRA brain PET scans for validation of the radioligand; (2) generate estimates of the whole body and internal organ radiation absorbed doses from exposure to single iv administrations of [18F]XTRA in healthy human subjects; and (3) determine brain distribution of [18F]XTRA in patients with Alzheimer's disease.


Condition Intervention
Measure of Uptake of XTRA in the Brain.
Radiation: Positron Emission Tomagraphy (PET) Imaging

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA

Resource links provided by NLM:


Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • PET Imaging of extrathalamic α4β2-nicotinic acetylcholine receptors in health and disease with [18F]XTRA [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Measures brain uptake of F18 XTRA


Estimated Enrollment: 60
Study Start Date: February 2013
Estimated Study Completion Date: February 2016
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Young healthy individuals (ages 18-50)
Positron Emission Tomagraphy (PET) Imaging
Radiation: Positron Emission Tomagraphy (PET) Imaging
Experimental: Elderly healthy individuals (ages 60-85)
Positron Emission Tomagraphy (PET) Imaging
Radiation: Positron Emission Tomagraphy (PET) Imaging
Patients with Alzheimer's disease or mild cognitive impairment
Positron Emission Tomagraphy (PET) Imaging
Radiation: Positron Emission Tomagraphy (PET) Imaging

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

The population consists of healthy adults 18-85 years of age. There is no race or sex bias in our recruitment.

a. Inclusion criteria.

  1. healthy volunteer, 18-80 years of age, and in portion 2, patient with Alzheimer's disease or patient with mild cognitive impairment (age 60-80 years)
  2. screening laboratory tests will be obtained for subjects within a 10-day period prior to the PET study and the results must be within normal limits for gender and age. These tests will be repeated with a 10-day window following the PET study.
  3. ECG conducted within a 10-day period prior to the PET study. The ECG will be repeated within 10 days following the study.
  4. No contraindications to MRI scanning if MRI is to be obtained in the section for which the subject participates. These contraindications include pacemakers, metallic implants/prosthesis or prohibitive claustrophobia, etc.
  5. No contraindications to PET scanning to include pregnancy, etc. For females of childbearing potential, negative serum pregnancy test obtained within a 10-day period prior to PET study
  6. Subject agrees to return to the Hospital for f/u ECG and laboratory testing of blood and urine

Exclusion Criteria:

  1. Participants with history of epilepsy, focal structural CNS abnormality such as stroke, or arteriovenous malformation
  2. History of head injury with loss of consciousness > 1 hour,
  3. Active substance abuse (drugs or alcohol) or active nicotine use
  4. ECG demonstrating the participant is not in a sinus rhythm or is having acute ischemia
  5. Any medical condition that in the opinion of the study investigators would constitute a safety risk to the subject.
  6. Any radiation exposure in the past calendar year that in combination with the radiation exposure from this study would exceed 5 rem
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01894646

Contacts
Contact: Martin G Pomper, Ph.D 410-955-2789 mpomper1@jhmi.edu
Contact: Jennifer M Coughlin, MD 410-746-6072 jcoughl2@jhmi.edu

Locations
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21287
Contact: Martin G Pomper, Ph.D    410-955-2789    mpomer1@jhmi.edu   
Principal Investigator: Martin G Pomper, Ph.D         
Sponsors and Collaborators
Johns Hopkins University
National Institutes of Health (NIH)
  More Information

Responsible Party: Martin G. Pomper, MD, PhD, Professor, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT01894646     History of Changes
Other Study ID Numbers: NA_00076249 
Study First Received: June 27, 2013
Last Updated: March 30, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Acetylcholine
Vasodilator Agents
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 23, 2016